Study Links Accelerated Epigenetic Age to Early Pregnancy Risk of Preeclampsia

A peer-reviewed study indicates that accelerated maternal biological age, estimated via Hannum's epigenetic clock in early pregnancy, serves as a predictive biomarker for preeclampsia risk.

Researchers evaluated whether maternal biological age, estimated from early pregnancy DNA methylation (DNAm) blood samples, could predict the development of preeclampsia.

The study analyzed data from two cohorts: a prospective cohort of pregnant women in the upper Midwest (Midwest cohort) and a cohort from the Prenatal Exposures & Preeclampsia Prevention Project (PEPP3).

Using machine-learning methods, including LASSO regression and Random Forest, the researchers identified that accelerated biological aging per the Hannum epigenetic clock, higher chronological age, and higher gestational weight gain were important predictors of preeclampsia.

Of the epigenetic clocks tested (Hannum, Horvath, and PhenoAge), only the Hannum clock demonstrated unique predictive power for preeclampsia across both cohorts.

Preeclampsia is a severe gestational complication with a historically limited capacity for early-pregnancy prediction and screening.

The findings suggest that accelerated biological aging is present in early pregnancy in women who later develop preeclampsia, implying that systemic cellular aging pathways may underlie the pathophysiology of the condition.

By demonstrating that Hannum's epigenetic clock holds predictive utility, the study validates the clinical application of longevity diagnostics to acute, pregnancy-related health outcomes.

This discovery could drive the development of clinical maternal epigenetic screening tests, expanding the addressable market for epigenetic diagnostic developers.

The application of machine-learning-derived epigenetic clocks to obstetric care highlights an emerging intersection between longevity profiling and maternal-fetal clinical medicine.

Diagnostic developers may utilize these findings to validate target panels focusing on Hannum-clock-specific DNA methylation sites for prenatal risk stratification.

Further clinical validation of Hannum's epigenetic clock in larger and geographically diverse patient populations to establish precise sensitivity and specificity thresholds.

Potential research exploring whether interventions that optimize metabolic health or manage biological age metrics can mitigate preeclampsia risk in high-risk patients.